BCAT2 (BCAT(m)) is the mitochondrial branched-chain-amino-acid aminotransferase, a class-IV pyridoxal 5'-phosphate (PLP)-dependent enzyme (EC 2.6.1.42) that catalyzes the first, reversible step of branched-chain amino acid (BCAA) catabolism. It transaminates L-leucine, L-isoleucine and L-valine with 2-oxoglutarate (alpha-ketoglutarate) to yield the corresponding branched-chain 2-oxo (keto) acids (4-methyl-2-oxopentanoate/KIC, (S)-3-methyl-2-oxopentanoate/KMV and 3-methyl-2-oxobutanoate/KIV) plus L-glutamate. The branched-chain keto acids are then passed to the mitochondrial branched-chain ketoacid dehydrogenase (BCKDH) complex for irreversible oxidative decarboxylation. The enzyme functions as a PLP-bound homodimer in the mitochondrial matrix, with the PLP cofactor forming a Schiff base (internal aldimine) to an active-site lysine (Lys-229), and carries a redox-active CXXC center (Cys-342/Cys-345) near the active site that couples catalysis to thiol redox state. BCAT2 is broadly expressed with highest activity in extrahepatic tissues such as skeletal muscle; the paralog BCAT1 is the cytosolic isozyme. Because BCAAs are essential amino acids in humans, the physiological direction of the reaction is catabolic (nitrogen removal), and loss of BCAT2 function causes an autosomal-recessive inborn error of metabolism (hypervalinemia and hyperleucine-isoleucinemia) with elevated plasma BCAAs.
| GO Term | Evidence | Action | Reason |
|---|---|---|---|
| GO:0005739 mitochondrion | IBA GO_REF:0000033 | ACCEPT | Summary: Phylogenetic (PAN-GO) inference that BCAT2 is active in the mitochondrion. Consistent with the cleaved N-terminal mitochondrial transit peptide (residues 1-27) and with all experimental localization evidence. Reason: BCAT2 has a 27-residue mitochondrial targeting presequence and is well established as a mitochondrial-matrix enzyme; the IBA is correct. Mitochondrial matrix (GO:0005759) is the more specific location captured elsewhere in the annotation set. Supporting Evidence: PMID:9165094 encode mature proteins of 41.2 and 41.3 kDa with presequences of 27 amino acids |
| GO:0006550 L-isoleucine catabolic process | IBA GO_REF:0000033 | ACCEPT | Summary: Phylogenetic inference that BCAT2 is involved in L-isoleucine catabolism. BCAT2 transaminates isoleucine as the committed first step of its catabolism. Reason: Isoleucine transamination is a core BCAT2 activity (GO:0052656), and the enzyme initiates isoleucine catabolism. Direct process annotation is appropriate and core. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0006574 L-valine catabolic process | IBA GO_REF:0000033 | ACCEPT | Summary: Phylogenetic inference that BCAT2 is involved in L-valine catabolism, initiating valine breakdown by transamination to 3-methyl-2-oxobutanoate. Reason: Valine transamination (GO:0052655) is a core BCAT2 activity; the enzyme initiates valine catabolism. Valine is the most conspicuously elevated BCAA in BCAT2 deficiency, underscoring its physiological role here. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0052654 L-leucine:2-oxoglutarate transaminase activity | IBA GO_REF:0000033 | ACCEPT | Summary: Phylogenetic inference of L-leucine:2-oxoglutarate transaminase activity, one of the three substrate-specific BCAT activities. Corroborated by IDA (PMID:8702755) and Rhea IEA. Reason: This substrate-specific molecular function is directly demonstrated for BCAT2 and is one of its core enzymatic activities. Supporting Evidence: PMID:8702755 code for cytosolic and mitochondrial branched-chain amino acid aminotransferases |
| GO:0052655 L-valine:2-oxoglutarate transaminase activity | IBA GO_REF:0000033 | ACCEPT | Summary: Phylogenetic inference of L-valine:2-oxoglutarate transaminase activity. Corroborated by IDA (PMID:8702755) and Rhea IEA (RHEA:24813). Reason: Core substrate-specific transaminase activity of BCAT2, directly measured with valine as substrate. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0052656 L-isoleucine:2-oxoglutarate transaminase activity | IBA GO_REF:0000033 | ACCEPT | Summary: Phylogenetic inference of L-isoleucine:2-oxoglutarate transaminase activity. Corroborated by IDA (PMID:8702755) and Rhea IEA (RHEA:24801). Reason: Core substrate-specific transaminase activity of BCAT2, directly measured with isoleucine as substrate. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0003824 catalytic activity | IEA GO_REF:0000002 | MARK AS OVER ANNOTATED | Summary: InterPro2GO mapping to the root catalytic-activity term. Correct but uninformative: BCAT2 is a specific PLP-dependent transaminase. Reason: GO:0003824 is a very general parent of the specific branched-chain aminotransferase activity (GO:0004084) and substrate-specific transaminase terms already annotated. It conveys no information beyond "is an enzyme" and is subsumed by the more precise MF annotations. |
| GO:0004084 branched-chain-amino-acid:2-oxoglutarate transaminase activity | IEA GO_REF:0000120 | ACCEPT | Summary: Combined multi-method IEA (ARBA + orthology + InterPro + EC:2.6.1.42) assigning the general branched-chain aminotransferase molecular function. This is the correct core EC-level activity. Reason: GO:0004084 is the primary molecular function of BCAT2 (EC 2.6.1.42) and is independently supported by direct experimental evidence (IDA PMID:8702755) and TAS (PMID:9165094). Supporting Evidence: PMID:8702755 code for cytosolic and mitochondrial branched-chain amino acid aminotransferases |
| GO:0005739 mitochondrion | IEA GO_REF:0000120 | ACCEPT | Summary: IEA localization to mitochondrion (orthology to mouse O35855 plus UniProt SubCell SL-0173). Consistent with all other localization evidence. Reason: Mitochondrial localization is firmly established; matrix is the specific compartment. Supporting Evidence: PMID:9165094 encode mature proteins of 41.2 and 41.3 kDa with presequences of 27 amino acids |
| GO:0009081 branched-chain amino acid metabolic process | IEA GO_REF:0000002 | KEEP AS NON CORE | Summary: InterPro2GO mapping to the general BCAA metabolic process. Correct but a broad parent of the specific catabolic-process annotations. Reason: GO:0009081 (BCAA metabolic process) is a correct but general parent of the more specific and physiologically directional BCAA catabolic process (GO:0009083) and the amino-acid-specific catabolic terms already annotated. Keep as non-core; the catabolic terms carry the core signal. |
| GO:0009082 branched-chain amino acid biosynthetic process | IEA GO_REF:0000117 | MARK AS OVER ANNOTATED | Summary: ARBA machine-learning IEA (and an older TAS) annotating branched-chain amino acid BIOSYNTHETIC process. The BCAT reaction is chemically reversible, but in humans BCAAs are essential and are not synthesized de novo; the physiological direction is catabolic. Reason: The reversible transamination can in principle re-aminate branched-chain keto acids, but net de novo BCAA biosynthesis is a bacterial/plant/fungal role of BCAT-family enzymes (e.g. IlvE), not the human physiological function. The biosynthetic-process annotation is transferred from the family/EC and over-states the in vivo role; the catabolic annotations are correct and core. (Retained as an over-annotation rather than removed, since the underlying reversible chemistry is real.) Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0009083 branched-chain amino acid catabolic process | IEA GO_REF:0000117 | ACCEPT | Summary: ARBA IEA to branched-chain amino acid catabolic process. This is the correct core biological process for BCAT2 and is independently supported by direct experimental evidence (IDA on the same term, PMID:8702755). Reason: BCAT2 catalyzes the committed first step of BCAA catabolism; this is its central physiological role. Supporting Evidence: PMID:8702755 code for cytosolic and mitochondrial branched-chain amino acid aminotransferases file:human/BCAT2/BCAT2-deep-research-falcon.md BCAT2 catalyzes the first step in mitochondrial BCAA catabolism |
| GO:0052654 L-leucine:2-oxoglutarate transaminase activity | IEA GO_REF:0000116 | ACCEPT | Summary: Rhea-based IEA (RHEA:18321) for L-leucine:2-oxoglutarate transaminase activity. Matches the UniProt CATALYTIC ACTIVITY reaction for leucine. Reason: Directly corresponds to a UniProt-documented catalytic reaction of BCAT2 and duplicates the experimentally supported (IDA/IBA) substrate-specific MF; correct and core. Supporting Evidence: PMID:8702755 code for cytosolic and mitochondrial branched-chain amino acid aminotransferases |
| GO:0052655 L-valine:2-oxoglutarate transaminase activity | IEA GO_REF:0000116 | ACCEPT | Summary: Rhea-based IEA (RHEA:24813) for L-valine:2-oxoglutarate transaminase activity, matching the UniProt CATALYTIC ACTIVITY reaction for valine. Reason: Directly corresponds to a UniProt-documented catalytic reaction of BCAT2; core substrate-specific activity. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0052656 L-isoleucine:2-oxoglutarate transaminase activity | IEA GO_REF:0000116 | ACCEPT | Summary: Rhea-based IEA (RHEA:24801) for L-isoleucine:2-oxoglutarate transaminase activity, matching the UniProt CATALYTIC ACTIVITY reaction for isoleucine. Reason: Directly corresponds to a UniProt-documented catalytic reaction of BCAT2; core substrate-specific activity. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0005515 protein binding | IPI PMID:28514442 Architecture of the human interactome defines protein commun... | MARK AS OVER ANNOTATED | Summary: Interaction detected in the BioPlex 2.0 high-throughput AP-MS interactome screen (interactors include HSPD1/P10809 and YBEY/P58557). "Protein binding" is uninformative about BCAT2's molecular function. Reason: GO:0005515 "protein binding" from a proteome-scale AP-MS screen conveys no specific functional information and is discouraged for core-function purposes. Per curation policy the experimental IPI is retained rather than removed, but it is marked as an over-annotation. (The BCAT2-HSPD1/HSP60 co-purification plausibly reflects mitochondrial chaperone association rather than a discrete functional partnership.) Supporting Evidence: PMID:28514442 robust affinity purification-mass spectrometry methodology to elucidate protein interaction networks and co-complexes |
| GO:0005515 protein binding | IPI PMID:29568061 An AP-MS- and BioID-compatible MAC-tag enables comprehensive... | MARK AS OVER ANNOTATED | Summary: Interaction (with HSPD1/P10809) detected using the MAC-tag AP-MS/BioID proximity-labeling platform. Bare "protein binding" from a high-throughput mapping method. Reason: High-throughput proximity/AP-MS "protein binding" is uninformative for BCAT2 core function. Retained as an experimental IPI per policy but marked as over-annotation; the HSPD1/HSP60 association is consistent with the mitochondrial matrix chaperone environment rather than a specific functional interaction. Supporting Evidence: PMID:29568061 comprehensive mapping of protein interactions and subcellular localizations |
| GO:0005515 protein binding | IPI PMID:33961781 Dual proteome-scale networks reveal cell-specific remodeling... | MARK AS OVER ANNOTATED | Summary: Interactions (HSPD1/P10809, YBEY/P58557) from the BioPlex 3.0 dual proteome-scale AP-MS interactome. Bare "protein binding" from a high-throughput screen. Reason: Proteome-scale AP-MS "protein binding" is uninformative about BCAT2's molecular function. Retained as an experimental IPI per policy, marked as over-annotation. Supporting Evidence: PMID:33961781 cell-specific remodeling of the human interactome |
| GO:0005515 protein binding | IPI PMID:40205054 Multimodal cell maps as a foundation for structural and func... | MARK AS OVER ANNOTATED | Summary: Interactions (HSPD1/P10809, YBEY/P58557) from a multimodal cell-map interactome dataset. Bare "protein binding" from a high-throughput mapping study. Reason: High-throughput interactome "protein binding" is uninformative for BCAT2 core function. Retained as an experimental IPI per policy, marked as over-annotation. Supporting Evidence: PMID:40205054 Multimodal cell maps as a foundation for structural and functional genomics |
| GO:0005759 mitochondrial matrix | IEA GO_REF:0000107 | ACCEPT | Summary: Ensembl-Compara orthology IEA (from mouse) placing BCAT2 activity in the mitochondrial matrix, the specific compartment where BCAA transamination occurs. Reason: Mitochondrial matrix is the correct, specific subcellular location for this soluble matrix enzyme, consistent with its cleaved transit peptide and TAS/Reactome annotations. Supporting Evidence: PMID:9165094 encode mature proteins of 41.2 and 41.3 kDa with presequences of 27 amino acids |
| GO:0006552 L-leucine catabolic process | IEA GO_REF:0000107 | ACCEPT | Summary: Ensembl-Compara orthology IEA (from mouse) for L-leucine catabolic process. BCAT2 initiates leucine catabolism by transamination to 4-methyl-2-oxopentanoate (KIC). Reason: Leucine transamination (GO:0052654) is a core BCAT2 activity and the enzyme initiates leucine catabolism; the process annotation is appropriate and core. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0006574 L-valine catabolic process | IEA GO_REF:0000107 | ACCEPT | Summary: Ensembl-Compara orthology IEA (from mouse) for L-valine catabolic process. Duplicates the IBA valine-catabolism annotation; correct and core. Reason: BCAT2 initiates valine catabolism; core biological process. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0097009 energy homeostasis | IEA GO_REF:0000107 | KEEP AS NON CORE | Summary: Ensembl-Compara orthology IEA (from mouse) for energy homeostasis. BCAA catabolism feeds acetyl-CoA/succinyl-CoA into the TCA cycle and BCAT2 loss alters energy expenditure in mice, but this is a broad downstream physiological consequence rather than the enzyme's molecular role. Reason: Energy homeostasis is a general, pleiotropic downstream process to which BCAA catabolism contributes indirectly (e.g. BCAT2-knockout mice show increased energy expenditure). It is not the core enzymatic function; keep as non-core. |
| GO:0005739 mitochondrion | IDA GO_REF:0000052 | ACCEPT | Summary: Direct immunofluorescence localization (Human Protein Atlas) placing BCAT2 in the mitochondrion. Reason: Experimental (IDA) immunofluorescence confirms mitochondrial localization, in agreement with all other evidence; matrix is the specific compartment. |
| GO:0005739 mitochondrion | ISS GO_REF:0000024 | ACCEPT | Summary: Sequence-similarity localization to mitochondrion, transferred from rat ortholog (O35854). Consistent with the transit peptide and experimental data. Reason: Mitochondrial localization is firmly established across evidence types. Supporting Evidence: PMID:9165094 encode mature proteins of 41.2 and 41.3 kDa with presequences of 27 amino acids |
| GO:0009083 branched-chain amino acid catabolic process | IDA PMID:8702755 Two yeast homologs of ECA39, a target for c-Myc regulation, ... | ACCEPT | Summary: Direct experimental evidence that BCAT2 participates in BCAA catabolism: BCAT activity toward leucine, isoleucine and valine was measured, and the human/yeast homologs encode the branched-chain aminotransferases initiating BCAA breakdown. Reason: This is the core biological process of BCAT2, supported by direct enzymatic assays with all three BCAA substrates. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0050873 brown fat cell differentiation | ISS GO_REF:0000024 | KEEP AS NON CORE | Summary: Sequence-similarity annotation transferred from mouse (O35855): BCAA catabolism supplies lipogenic acetyl-CoA that EP300/p300 uses to acetylate and inhibit PRDM16, preventing adipose browning. A real but indirect metabolic-signalling role, downstream of the catabolic function. Reason: This links BCAT2 to a specific downstream developmental/metabolic output (brown fat differentiation) via acetyl-CoA supply and PRDM16 regulation. It is genuine (documented in mouse orthologs) but is a peripheral, indirect role rather than BCAT2's core enzymatic function; keep as non-core. Supporting Evidence: UniProtKB:O35855 acetyl-CoA derived from branched chain amino acid catabolism is used by EP300/p300 to acetylate and inhibit PRDM16, thereby preventing adipose tissue browning |
| GO:0004084 branched-chain-amino-acid:2-oxoglutarate transaminase activity | IDA PMID:8702755 Two yeast homologs of ECA39, a target for c-Myc regulation, ... | ACCEPT | Summary: Direct experimental demonstration of branched-chain aminotransferase activity for the cloned mitochondrial enzyme, assayed with leucine, isoleucine and valine as substrates. Reason: This is the core molecular function of BCAT2 (EC 2.6.1.42), established by direct enzymatic assay. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:1903444 negative regulation of brown fat cell differentiation | ISS GO_REF:0000024 | KEEP AS NON CORE | Summary: Sequence-similarity annotation transferred from mouse (MGI:1276534) for negative regulation of brown fat cell differentiation, via BCAA-catabolism-derived acetyl-CoA and EP300/PRDM16 signalling. Reason: Same indirect brown-fat/PRDM16 axis as GO:0050873; a genuine downstream metabolic-signalling role documented in mouse but peripheral to BCAT2's core transaminase function. Keep as non-core. Supporting Evidence: UniProtKB:O35855 acetyl-CoA derived from branched chain amino acid catabolism is used by EP300/p300 to acetylate and inhibit PRDM16, thereby preventing adipose tissue browning |
| GO:0005739 mitochondrion | HTP PMID:34800366 Quantitative high-confidence human mitochondrial proteome an... | ACCEPT | Summary: High-throughput proteomic assignment of BCAT2 to the high-confidence human mitochondrial proteome (MitoCoP). Reason: Corroborates mitochondrial localization by an orthogonal high-throughput proteomics method, consistent with all other evidence. Supporting Evidence: PMID:34800366 defined a mitochondrial high-confidence proteome of >1,100 proteins (MitoCoP) |
| GO:0052654 L-leucine:2-oxoglutarate transaminase activity | IDA PMID:8702755 Two yeast homologs of ECA39, a target for c-Myc regulation, ... | ACCEPT | Summary: Direct experimental demonstration of L-leucine transaminase activity for the mitochondrial branched-chain aminotransferase. Reason: Core substrate-specific molecular function, directly measured with leucine as substrate. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0052655 L-valine:2-oxoglutarate transaminase activity | IDA PMID:8702755 Two yeast homologs of ECA39, a target for c-Myc regulation, ... | ACCEPT | Summary: Direct experimental demonstration of L-valine transaminase activity for the mitochondrial branched-chain aminotransferase. Reason: Core substrate-specific molecular function, directly measured with valine as substrate. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0052656 L-isoleucine:2-oxoglutarate transaminase activity | IDA PMID:8702755 Two yeast homologs of ECA39, a target for c-Myc regulation, ... | ACCEPT | Summary: Direct experimental demonstration of L-isoleucine transaminase activity for the mitochondrial branched-chain aminotransferase. Reason: Core substrate-specific molecular function, directly measured with isoleucine as substrate. Supporting Evidence: PMID:8702755 Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates |
| GO:0005759 mitochondrial matrix | TAS Reactome:R-HSA-508179 | ACCEPT | Summary: Reactome traceable-author-statement placing the BCAT2 reaction in the mitochondrial matrix (reverse direction: keto acids + glutamate to BCAAs + alpha-ketoglutarate). Reason: Mitochondrial matrix is the correct specific location for this enzyme; Reactome annotation is consistent with all other evidence. |
| GO:0005759 mitochondrial matrix | TAS Reactome:R-HSA-70724 | ACCEPT | Summary: Reactome traceable-author-statement placing the BCAT2 reaction in the mitochondrial matrix (forward catabolic direction: BCAAs + alpha-ketoglutarate to keto acids + glutamate). Reason: Mitochondrial matrix is the correct specific location for this enzyme; consistent with all other evidence. |
| GO:0004084 branched-chain-amino-acid:2-oxoglutarate transaminase activity | TAS PMID:9165094 Cloning of the rat and human mitochondrial branched chain am... | ACCEPT | Summary: Traceable author statement (cloning of rat and human BCATm) supporting the branched-chain aminotransferase molecular function. This paper established the BCAT1/BCAT2 nomenclature and showed the cloned enzyme has BCAT activity. Reason: Corroborates the core EC-level molecular function of BCAT2 with TAS from the defining cloning paper. Supporting Evidence: PMID:9165094 the protein exhibits BCAT activity and correct processing of the mitochondrial targeting sequence |
| GO:0005739 mitochondrion | TAS PMID:9165094 Cloning of the rat and human mitochondrial branched chain am... | ACCEPT | Summary: Traceable author statement for mitochondrial localization from the BCATm cloning paper, which demonstrated correct processing of the mitochondrial targeting presequence. Reason: Mitochondrial localization is established; the cloning paper showed proper mitochondrial targeting-sequence processing. Supporting Evidence: PMID:9165094 the protein exhibits BCAT activity and correct processing of the mitochondrial targeting sequence |
| GO:0009082 branched-chain amino acid biosynthetic process | TAS PMID:8702755 Two yeast homologs of ECA39, a target for c-Myc regulation, ... | MARK AS OVER ANNOTATED | Summary: Older TAS annotating branched-chain amino acid BIOSYNTHETIC process, presumably reflecting the chemically reversible transamination. In humans BCAAs are essential and not synthesized de novo, so the physiological direction is catabolic. Reason: The reversible reaction can re-aminate branched-chain keto acids, but net BCAA biosynthesis is a microbial/plant role of BCAT-family enzymes, not the human function; humans require dietary BCAAs. The biosynthetic-process annotation over-states the in vivo role. Retained as an over-annotation (the reversible chemistry is real) rather than removed. Supporting Evidence: PMID:8702755 code for cytosolic and mitochondrial branched-chain amino acid aminotransferases |
| GO:0030170 pyridoxal phosphate binding | IDA PMID:8702755 Two yeast homologs of ECA39, a target for c-Myc regulation, ... | NEW | Summary: Proposed annotation (not in current GOA): BCAT2 binds pyridoxal 5'-phosphate (PLP) as its essential catalytic cofactor. UniProt records PLP as the cofactor (COFACTOR, from crystallographic studies) and a Schiff-base MOD_RES at Lys-229; PLP binding is required for the demonstrated aminotransferase activity. Reason: PLP-binding is a well-established, structurally and biochemically documented molecular function of this class-IV PLP-dependent aminotransferase (many BCATm crystal structures resolve the PLP cofactor; the Schiff-base lysine is annotated in UniProt) and directly underlies its catalytic activity. It is currently missing from GOA and is added here as a core function. Supporting Evidence: file:human/BCAT2/BCAT2-uniprot.txt Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326; |
| GO:0005515 protein binding | IPI PMID:28514442 Architecture of the human interactome defines protein commun... | KEEP AS NON CORE | Summary: The reported physical interaction is retained as non-core; generic protein binding does not specify the catalytic mechanism. Reason: Physical interaction and catalytic function are distinct claims. The observed interaction does not independently establish a new enzyme activity. |
| GO:0005515 protein binding | IPI PMID:33961781 Dual proteome-scale networks reveal cell-specific remodeling... | KEEP AS NON CORE | Summary: The reported physical interaction is retained as non-core; generic protein binding does not specify the catalytic mechanism. Reason: Physical interaction and catalytic function are distinct claims. The observed interaction does not independently establish a new enzyme activity. |
| GO:0005515 protein binding | IPI PMID:40205054 Multimodal cell maps as a foundation for structural and func... | KEEP AS NON CORE | Summary: The reported physical interaction is retained as non-core; generic protein binding does not specify the catalytic mechanism. Reason: Physical interaction and catalytic function are distinct claims. The observed interaction does not independently establish a new enzyme activity. |
Loading supporting contentβ¦
Download this section (compressed HTML)Q: In human tissues, does BCAT2 carry any physiologically relevant biosynthetic (re-amination) flux toward BCAAs, or is the net direction exclusively catabolic given the essentiality of dietary BCAAs?
Q: To what extent do the reported BCAT2 protein-protein interactions (e.g. with HSPD1/HSP60) and the CXXC-dependent metabolon with the BCKDH E1 subunit represent discrete functional partnerships versus co-purification within the mitochondrial matrix?
Experiment: Quantify BCAA-to-BCKA flux directionality in situ (e.g. stable-isotope 15N/13C tracing) in BCAT2-expressing human muscle vs liver models to determine whether any net biosynthetic re-amination occurs physiologically.
Experiment: Reconstitute the BCAT2-BCKDH E1 metabolon in vitro with reduced vs oxidized CXXC-center BCAT2 (and C342A/C345A mutants) to test how the redox state of the CXXC center gates substrate channeling and overall BCAA oxidation rate.
Loading supporting contentβ¦
Download this section (compressed HTML)Loading supporting contentβ¦
Download this section (compressed HTML)Loading supporting contentβ¦
Download this section (compressed HTML)